Groningen Research Institute of Pharmacy, Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, the Netherlands; GE Healthcare Radiopharmacy Zwolle, Zwolle, the Netherlands.
Department of Nuclear Medicine, Isala Hospital, Zwolle, the Netherlands; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.
Semin Nucl Med. 2019 Sep;49(5):382-410. doi: 10.1053/j.semnuclmed.2019.06.006.
Diagnostic radiopharmaceuticals used in nuclear medicine can cause adverse events. Information on these adverse events is available in case reports and databases but may not be readily accessible to healthcare professionals. This systematic review provides an overview of adverse events of diagnostical radiopharmaceuticals and their characteristics. A median frequency for adverse events in diagnostical radiopharmaceuticals of 1.63 (interquartile range: 1.09-2.29) per 100,000 is reported. Most common are skin and subcutaneous tissue disorders, and general disorders and administration site conditions. Many adverse events reported are minor in severity, although 6.7% can be classified as important. In rare cases, adverse events are serious and potentially life-threatening. With the introduction of new radiopharmaceuticals and the increasing use of positron emission tomography-computed tomography, previously unknown adverse events may be detected in daily practice. Future work should cover the experience of the patient with adverse events from diagnostic radiopharmaceuticals.
核医学中使用的诊断放射性药物会引起不良反应。这些不良反应的信息可在病例报告和数据库中获得，但可能不容易为医疗保健专业人员所获取。本系统评价提供了诊断放射性药物不良反应及其特征的概述。报告的诊断放射性药物不良反应中位数频率为每 100,000 人中有 1.63（四分位距：1.09-2.29）。最常见的是皮肤和皮下组织疾病以及一般疾病和给药部位情况。报告的许多不良反应严重程度较轻，尽管有 6.7%可归类为重要。在极少数情况下，不良反应很严重，可能危及生命。随着新放射性药物的引入和正电子发射断层扫描-计算机断层扫描的使用增加，在日常实践中可能会发现以前未知的不良反应。未来的工作应涵盖诊断放射性药物不良反应患者的体验。
